Craft

Novo Nordisk

Stock Price

KR768.8

2024-10-29

Market Capitalization

KR4 T

2024-08-26

Revenue

KR309.1 B

FY, 2025

Novo Nordisk Summary

Company Summary

Overview
Novo Nordisk is a healthcare company that designs and manufactures pharmaceutical products. It offers insulins, glucagon-like peptide-1, oral antidiabetic agents, and other drugs. The company also provides pens, needles, an insulin dose guidance app Dose Check, etc. Novo Nordisk provides its products for diabetes, obesity, hemophilia, cardiovascular, and Alzheimer's disease treatment.
Type
Public
Status
Active
Founded
1923
HQ
Bagsværd, DK | view all locations
Website
https://www.novonordisk.com/
Cybersecurity rating
ESG rating
60-79 out of 100|View all ESG data
Sectors

Key People

  • Lars Fruergaard Jørgensen

    Lars Fruergaard Jørgensen, President and Chief Executive Officer

  • Monique Carter

    Monique Carter, Executive Vice President and Head of People & Organisation

  • Maziar Mike Doustdar

    Maziar Mike Doustdar, Executive Vice President and Head of International Operations

  • Ludovic Helfgott

    Ludovic Helfgott, Executive Vice President and Head of Rare Disease

Operating MetricsView all

Phase I Trials Products (Haemophilia)

1

Q4, 2021

Trials Products Approved (Obesity)

2

Q3, 2022

Phase III Trials Products (Obesity)

2
100.0%

Q3, 2022

LocationsView all

111 locations detected

  • Bagsværd HQ

    Denmark

    Novo Allé 1

  • Cambridge, MA

    United States

    255 Main St #10th

  • Clayton, NC

    United States

    3612 Powhatan Rd

  • Durham, NC

    United States

    5235 International Dr

  • Fremont, CA

    United States

    6300 Dumbarton Cir

  • Lebanon, NH

    United States

    9 Technology Dr, West Lebanon

and 105 others

Novo Nordisk Financials

Summary Financials

Revenue (Q1, 2026)
kr96.8B
Gross profit (Q1, 2026)
kr86.8B
Net income (Q1, 2026)
kr48.6B
Cash (Q1, 2026)
kr21.1B
EBIT (Q1, 2026)
kr59.6B
Enterprise value
$4.1T

Footer menu